EUVIMEDEUVIMED entdecken
Crossref

L26/P-877 Hormone replacement therapy for frozen embryo transfer is associated with increased hypertensive disorders in pregnancy: a temporally robust analysis

H. Kamiya, N. Iwami, N. HIrayama, T. Fujii, K. Takimoto, M. Kawamata, N. Ozawa, E. Watanabe, O. Moriwaka

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H. Kamiya und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Is hormone replacement therapy (HRT) frozen embryo transfer (FET) associated with a higher risk of hypertensive disorders of pregnancy (HDP) compared with natural cycle FET? Summary answer HRT-FET was associated with significantly higher HDP risk than natural cycle FET, with consistent findings across temporal models. What is known already FET can be performed using either natural cycles or HRT. Previous studies have suggested that HRT-FET may be associated with an increased risk of HDP, potentially related to the absence of a corpus luteum and altered angiogenic balance. However, findings have been inconsistent, and it remains unclear whether reported associations are robust to temporal changes in clinical practice and patient characteristics. Study design, size, duration This retrospective cohort study analyzed singleton deliveries following FET performed between 2018 and 2024. After excluding multiple gestations and incomplete records, 4,301 singleton pregnancies (339 natural cycle, 3,962 HRT) were included, enabling evaluation of effect size and temporal robustness over a 6-year period. Participants/materials, setting, methods Singleton pregnancies conceived by FET were classified as natural cycle or HRT. Multivariable logistic regression evaluated the association between endometrial preparation method and HDP, adjusting for maternal age, body mass index (BMI), embryo stage, number of embryos transferred, endometrial thickness, and year of transfer. Sensitivity analyses assessed stability across alternative temporal specifications. Main results and the role of chance In this singleton cohort (n = 4,301), HDP occurred in 9.3% of HRT-FET pregnancies compared with 4.7% of natural cycle FET pregnancies. After multivariable adjustment for maternal age, BMI, embryo stage, number of embryos transferred, endometrial thickness, and year of transfer, HRT-FET remained significantly associated with increased HDP risk (adjusted odds ratio 2.10, 95% CI 1.25–3.52, p = 0.005). Among singleton deliveries, the absolute risk of HDP was 9.2% in HRT-FET versus 4.9% in natural cycle FET (absolute risk difference [ARD] 4.34%, 95% CI 0.58–7.14), corresponding to a number needed to harm (NNH) of 23 (95% CI 14–173). In a marginal effects analysis based on the fully adjusted model, the predicted risk of HDP was 9.1% for HRT-FET and 5.2% for natural cycle FET, yielding an adjusted absolute risk difference of 3.90% (95% CI 0.92–6.41) and an adjusted NNH of 26 (95% CI 16–109). The absolute risk increase associated with HRT-FET was progressively larger in older and higher-BMI women (p-interaction for age = 0.041; p-interaction for BMI = 0.018). Sensitivity analyses accounting for temporal trends yielded consistent results, and no significant interaction between endometrial preparation method and year was observed (p = 0.52). Limitations, reasons for caution This observational study cannot establish causality, and residual confounding cannot be excluded. The natural cycle group was smaller than the HRT group, reflecting real-world clinical practice, which may limit precision for some secondary analyses. Wider implications of the findings These real-world findings demonstrate a temporally robust association between HRT-FET and increased HDP risk, supporting a role for corpus luteum-related pathways and consideration of natural cycle FET when feasible, with heightened surveillance for HDP in HRT-FET pregnancies Trial registration number No

Zitieren

APA

Kamiya, H., Iwami, N., HIrayama, N., Fujii, T., Takimoto, K., Kawamata, M., Ozawa, N., Watanabe, E., & Moriwaka, O. (2026). L26/P-877 Hormone replacement therapy for frozen embryo transfer is associated with increased hypertensive disorders in pregnancy: a temporally robust analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1201

Vancouver

Kamiya H, Iwami N, HIrayama N, Fujii T, Takimoto K, Kawamata M, et al. L26/P-877 Hormone replacement therapy for frozen embryo transfer is associated with increased hypertensive disorders in pregnancy: a temporally robust analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1201

BibTeX
@article{Kamiya2026,
  author = {Kamiya, H. and Iwami, N. and HIrayama, N. and Fujii, T. and Takimoto, K. and Kawamata, M. and Ozawa, N. and Watanabe, E. and Moriwaka, O.},
  title = {L26/P-877 Hormone replacement therapy for frozen embryo transfer is associated with increased hypertensive disorders in pregnancy: a temporally robust analysis},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1201}
}
Kostenlos starten →